HomeCompareCNPPF vs ABBV

CNPPF vs ABBV: Dividend Comparison 2026

CNPPF yields 4.31% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNPPF wins by $2696.37M in total portfolio value
10 years
CNPPF
CNPPF
● Live price
4.31%
Share price
$0.58
Annual div
$0.02
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2696.48M
Annual income
$2,581,385,552.33
Full CNPPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CNPPF vs ABBV

📍 CNPPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNPPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNPPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNPPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNPPF
Annual income on $10K today (after 15% tax)
$366.24/yr
After 10yr DRIP, annual income (after tax)
$2,194,177,719.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CNPPF beats the other by $2,194,156,663.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNPPF + ABBV for your $10,000?

CNPPF: 50%ABBV: 50%
100% ABBV50/50100% CNPPF
Portfolio after 10yr
$1348.29M
Annual income
$1,290,705,162.04/yr
Blended yield
95.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CNPPF
No analyst data
Altman Z
5.3
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNPPF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNPPFABBV
Forward yield4.31%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2696.48M$102.3K
Annual income after 10y$2,581,385,552.33$24,771.77
Total dividends collected$2688.30M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CNPPF vs ABBV ($10,000, DRIP)

YearCNPPF PortfolioCNPPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,562$861.75$11,550$430.00+$12.00CNPPF
2$14,233$1,862.30$13,472$627.96+$761.00CNPPF
3$19,515$4,285.30$15,906$926.08+$3.6KCNPPF
4$31,863$10,982.17$19,071$1,382.55+$12.8KCNPPF
5$67,610$33,516.25$23,302$2,095.81+$44.3KCNPPF
6$205,272$132,929.76$29,150$3,237.93+$176.1KCNPPF
7$974,019$754,377.23$37,536$5,121.41+$936.5KCNPPF
8$7,732,900$6,690,700.26$50,079$8,338.38+$7.68MCNPPF
9$107,561,325$99,287,121.69$69,753$14,065.80+$107.49MCNPPF
10$2,696,476,170$2,581,385,552.33$102,337$24,771.77+$2696.37MCNPPF

CNPPF vs ABBV: Complete Analysis 2026

CNPPFStock

China Overseas Property Holdings Limited, an investment holding company, provides property management services in Hong Kong, Macau, and the People's Republic of China. It operates through Property Management Services, Value-Added Services, and Car Parking Spaces Trading Business segments. The Property Management Services segment offers security, repair and maintenance, cleaning, and garden landscape maintenance services to mid-to high-end residential communities, commercial properties, government properties, and construction sites. The Value-Added Services segment offers engineering, vetting of building plans, facilities and equipment evaluation proposals, pre-delivery, move-in assistance, delivery inspection, engineering service quality monitoring and consulting services, etc. for property developers and other property management companies; and community asset management services and living service operations for residents, as well as commercial service operations. The Car Parking Spaces Trading Business segment engages in the trading of various car parking spaces. It is also involved in the provision of automation and other equipment upgrade services; property agency; information technology services; and service through online to offline platform. The company was formerly known as China Overseas Management Services International Limited and changed its name to China Overseas Property Holdings Limited in May 2015. The company was founded in 1986 and is headquartered in Hong Kong, Hong Kong. China Overseas Property Holdings Limited is a subsidiary of China Overseas Holdings Limited.

Full CNPPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CNPPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNPPF vs SCHDCNPPF vs JEPICNPPF vs OCNPPF vs KOCNPPF vs MAINCNPPF vs JNJCNPPF vs MRKCNPPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.